A magnifying glass highlights a red-and-yellow capsule among a scattered group of white tablets on a light blue background

istock-1169106144-1800x900

 A magnifying glass highlights a red-and-yellow capsule among a scattered group of white tablets on a light blue background

The disconnect between preclinical models and clinical outcomes remains a key challenge in drug development, especially as therapies become more complex. Traditional in vitro and in vivo models often lack the physiological relevance needed to predict drug-induced liver injury (DILI), a leading cause of candidate failure. In this webinar, experts explore how human and animal liver microphysiological systems (MPS) enhance DILI risk prediction and support more confident clinical progression.Topics to be covered<ul><li>Current limitations of traditional models in predicting clinical drug safety</li><li>How MPS improve the physiological relevance of preclinical liver models</li><li>Where organ-on-a-chip and MPS technologies fit into the drug development pipeline</li><li>Considerations for implementing liver MPS in early safety testing strategies</li></ul>

CN Bio is a leading organ-on-a-chip (OOC) company based in Cambridge, UK. CN Bio offers a portfolio of products and services to optimise the accuracy and efficiency of bringing new medicines to market; providing significant savings in cost and time to drug discovery and development pipelines.With more than a decade of experience in precision engineering and single and multi-organ microphysiology, CN Bio aims to transform the way human-relevant pre-clinical data is generated through the development of advanced, predictive human organ models. The Company&rsquo;s PhysioMimix&reg; OOC range of microphysiological systems (MPS) bridges the relevance gap between traditional cell culture, in vivo animal studies, and human trials by advancing towards the simulation of human biological conditions. The technology provides deep mechanistic insights to enable researchers to refine preclinical study design, reducing the number of animals required, and better preparing and informing studies ahead of the clinic to support safe, efficacious and efficient therapeutic development.

cn-bio-logo-colour-300mm

CN Bio

Microphysiological systems offer a promising solution to the long-standing challenge of predicting clinical drug safety outcomes from preclinical models.

Bridging the translational gap in liver toxicity testing

Microphysiological systems offer a promising solution to the long-standing challenge of predicting clinical drug safety outcomes from preclinical models.

Sponsored by